**Core Concept**
The question is testing the student's knowledge of novel oral anticoagulants (NOACs), a class of medications that target specific coagulation factors to prevent thrombosis. NOACs have gained popularity due to their ease of administration, predictable pharmacokinetics, and reduced risk of bleeding compared to traditional anticoagulants like warfarin.

**Why the Correct Answer is Right**
The correct answer is a non-target specific oral anticoagulant, which means it does not inhibit a specific coagulation factor like the others. Traditional oral anticoagulants like warfarin and acenocoumarol work by inhibiting vitamin K-dependent clotting factors (II, VII, IX, X), whereas NOACs target specific coagulation factors (factor IIa, factor Xa, or thrombin).

**Why Each Wrong Option is Incorrect**
**Option A:** This is a target-specific oral anticoagulant that inhibits factor Xa, a critical enzyme in the coagulation cascade. It's one of the most commonly used NOACs for stroke prevention in atrial fibrillation.

**Option C:** This is another target-specific oral anticoagulant that inhibits thrombin (factor IIa), another key enzyme in the coagulation cascade. It's used for the prevention of stroke in patients with non-valvular atrial fibrillation.

**Clinical Pearl / High-Yield Fact**
NOACs have a unique reversal profile, with specific antidotes available for each class. For example, idarucizumab is a specific antidote for dabigatran (Option C), while andexanet alfa is used to reverse apixaban (Option A).

**Correct Answer:** D. Warfarin